Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.76
+0.06500.39%
Post-market: 16.820.0611+0.36%19:59 EDT
Volume:5.20M
Turnover:87.53M
Market Cap:13.37B
PE:-14.99
High:17.32
Open:16.96
Low:16.66
Close:16.69
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.45
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.22
PE(LYR):-11.60

Loading ...

Stocks to Watch: Summit Therapeutics, Sangoma, Navitas

Dow Jones
·
Sep 29

Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment

TIPRANKS
·
Sep 29

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

TIPRANKS
·
Sep 29

AstraZeneca makes $2B equity investment in Summit Therapeutics

TIPRANKS
·
Sep 29

Movement Alert|Summit Therapeutics PLC Rises 17.39% in After-Hours Trading, Multiple Late-Stage Clinical Catalysts Drive Momentum

Market Focus
·
Sep 29

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

THOMSON REUTERS
·
Sep 29

Summit Therapeutics - Co and AstraZeneca Plan Clinical Trial Collaboration for Ivonescimab with Multiple AstraZeneca Adcs

THOMSON REUTERS
·
Sep 29

Summit Therapeutics - Investment in Convertible Preferred Shares at $18.36 Per Share, Premium to Closing Price

THOMSON REUTERS
·
Sep 29

AstraZeneca Makes $2 Billion Equity Investment in Summit Therapeutics Via Convertible Preferred Shares

Reuters
·
Sep 29

Bernstein Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 26

Piper Sandler Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 25

Movement Alert|Summit Therapeutics PLC Falls 5.03% in Regular Trading, FDA Approval Uncertainty Continues to Weigh on Shares

Market Focus
·
Sep 24

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Sep 23

Summit Therapeutics Says Phase III HARMONi-GI1 Trial of Ivonescimab in Biliary Tract Cancer Shows OS Superiority vs AstraZeneca’s Imfinzi Regimen

Reuters
·
Sep 22

Harmoni-Gi1, a Phase Iii Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to be Showcased in Presidential Symposium at Esmo 2026

THOMSON REUTERS
·
Sep 22

Movement Alert|Summit Therapeutics PLC Falls 5.13% in Regular Trading, Trading at $16.9

Market Focus
·
Sep 21

LEPAS Expands Its Presence Across European Markets, Bringing Elegant Mobility to More Consumers

GlobeNewswire
·
Sep 21

Updated Harmoni Data Presented at Wclc 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

THOMSON REUTERS
·
Sep 15

Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit

MT Newswires Live
·
Sep 15

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14